The currently available strategies to manipulate the light scattering signals of intensity or hydrodynamic diameter (D H) of nanoparticles and construct DLS immunosensors mainly involve the size change of individual nanoparticles upon target binding and the target-induced nanoparticle aggregation or self-assembly upon the antigen–antibody reaction. Inspired by this work, many research groups have extended DLS enhanced immunosensors for the detection of small molecules, metal ions, and microorganisms. By coupling the strong light scattering properties of gold nanoparticles with the dynamic light scattering (DLS) technique routinely used for nanoparticle size characterization, Huo’s group has pioneered the development of a DLS-based immunosensing platform for monitoring proteins. In recent years, increasing interest has been focused on exploring technologies to enhance the signal transduction for designing high-performance immunosensors. Although current methods succeed in achieving the specific detection of NT-proBNP, they are still compromised by insufficient sensitivity, long response time, large sample consumption and limited use in the field of point-of-care (POC) testing.ĭetecting trace target analytes in highly sensitive way usually depends on the sensitive transduction techniques and the effective signal reporting strategies. At present, versatile immunoassay approaches have been reported to improve the determination of NT-proBNP, including colorimetric, fluorescent, electrochemical, field effect transistor, photoelectrochemical, electrochemiluminescence, and surface-enhanced Raman scattering. Therefore, ultrasensitive detection for NT-proBNP is crucial for accurate clinical diagnosis and prognosis to reduce the hospitalization and mortality rates. In general, the population with the NT-proBNP concentrations exceeding 300 pg mL −1 is high risk for HF. N-terminal pro-brain natriuretic peptide (NT-proBNP) has been considered as a clinically recognized biomarker for early diagnosis of HF. Early diagnosis of HF contributes to timely intervention, treatment, and prognosis. Heart failure (HF) is one of the most common cardiovascular diseases, which often adversely affects cardiovascular health and has become a major cause of death in humans. Collectively, this work demonstrated the promising application of the designed boronate affinity amplified-DLS immunosensor for field or point-of-care testing of cis-diol-containing molecules. The DLS immunosensor was further characterized with good selectivity, accuracy, precision, reproducibility, and practicability. Owing to the multivalent and fast affinity recognition between NT-proBNP containing cis-diols and SiO the developed DLS immunosensor exhibited charming advantages over traditional immunoassays, including ultrahigh sensitivity with an LOD of 7.4 fg mL −1, fast response time (< 20 min), and small sample consumption (1 μL). Meanwhile, silica nanoparticles modified with phenylboronic acid (SiO were designed as the crosslinking agent to bridge the aggregation of MNPs in the presence of target NT-proBNP. After covalently coupling with antibodies, magnetic nanoparticles (MNPs) were employed as the nanoprobes to selectively capture trace amount of NT-proBNP from complex samples and facilitate DLS signal transduction. In this design, the boronate affinity recognition based on the interaction of boronic acid ligands and cis-diols was introduced to amplify the nanoparticle aggregation to enable highly sensitive DLS transduction, thereby lowering the limit of detection (LOD) of the methodology. Herein, we reported a new dynamic light scattering (DLS) immunosensing technology for the rapid and sensitive detection of glycoprotein N-terminal pro-brain natriuretic peptide (NT-proBNP).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |